Andy Chu is the SVP of Product and Technology at Providence’s innovation unit. They have launched four companies in recent years (Wildlfower, Xealth, Dexcare and just this week Praia). Andy talked a little about Praia, and more about both how Providence comes up with solutions and gets them through their process, and also the inverse, how his group helps new companies get into Providence (not easy!). I also asked him about how big the impact of those hospital innovation groups actually is. And how AI will roll out. Also not easy!–Matthew Holt
#HealthTechDeals Episode 15| Clarify, Embedded Healthcare, Wildflower, Vivante Health, Gravie, Nice
We made it back from ViVE in one piece! Will Jess DaMassa stab me in the back Brutus-Style? Tune in to find out as we discuss deals: Clarify buys Embedded Healthcare; Wildflower raises $26 million; Vivante Health raises $16 million; Gravie raises $75 million; and Nice Healthcare raises $30 million.
–Matthew Holt
Transcript
Jess DaMassa:
Well, we made it back from Vive all in one piece and we landed squarely in the Ides of March. Will I stab Matthew Holt in the back Brutus-style? Tune to the March 15th episode of Health Tech DEALS. Oh Matthew Holt, those ruthless Romans, never trust an Italian. That’s the lesson here.
Matthew Holt:
Well, sad enough, I trusted you and you told me to buy some stocks. And now, have you seen digital digital health talks yesterday?
Matthew Holt:
Everybody off another 10%?
Jess DaMassa:
Okay, but how does that compare with the reality of everything else right now?
Matthew Holt:
I don’t know. Somehow, Teladoc was about 300 a year ago
Jess DaMassa:
Don’t even talk to me about Teladoc.
Matthew Holt:
Now it’s around 50.
Continue reading…
